Search Results
Your search for The ASCO Post,The ASCO Post matches 17399 pages
Showing 1 - 50Recent Advances in Treating Diffuse Large B-Cell Lymphoma
The disease we now call diffuse large B-cell lymphoma (DLBCL) has gone by the names of reticulum cell sarcoma, diffuse histiocytic lymphoma, and diffuse large cell lymphoma, and included both lymphomas of B cells and T cells. We now know DLBCL is still heterogenous and some subtypes might benefit...
Antimicrobial Resistance in Outpatients With Cancer
In a U.S. multicenter retrospective cohort study reported in The Lancet Oncology, Gupta et al evaluated whether antimicrobial resistance was more common in pathogenic bacterial isolates from outpatients with cancer than in outpatients without cancer. Study Details The study involved data from the...
Reduced-Dose Chemoradiotherapy for Early-Stage Anal Cancer
In a UK phase II trial (PLATO-ACT4) reported in The Lancet Oncology, Gilbert et al evaluated whether short-term results showed good complete response rates with both standard-dose and reduced-dose chemoradiotherapy in patients with localized squamous cell carcinoma of the anus. Study Details In the ...
Risk of Gynecologic Cancers After 5 Years of Testosterone Use
Transmasculine and gender-diverse patients receiving testosterone as part of their hormone therapy may not be at an increased risk of developing gynecologic cancers in the first years of treatment, according to a recent study published by Vestering et al in eClinicalMedicine. Background Many...
Novel Prediction Model for Hearing Loss From Chemotherapy in Pediatric Patients With Cancer
In a study reported in the Journal of Clinical Oncology, Millstein et al attempted to develop a predictive model—Pediatric Holistic Evaluation of Auditory Risk (PedsHEAR)—for hearing loss associated with cisplatin chemotherapy in children and adolescents with cancer. Study Details PedsHEAR was...
Neoadjuvant Therapy for IBD-Related Rectal Cancer
Total neoadjuvant therapy of intensified chemoradiotherapy was shown to be less effective for treating patients with rectal cancer with inflammatory bowel disease (IBD) than those with sporadic rectal cancer, according to study findings presented during Digestive Disease Week 2025. However, there...
Second-Line Endocrine Therapy With/Without Palbociclib Rechallenge in HR-Positive, HER2-Negative Advanced Breast Cancer
In a phase II trial (PALMIRA) reported in the Journal of Clinical Oncology, Llombart-Cussac et al evaluated whether palbociclib rechallenge with second-line alternative endocrine therapy may improve progression-free survival vs second-line alternative endocrine therapy alone. Study Details In the...
Retifanlimab-dlwr Approved for Anal Cancer
On May 15, the U.S. Food and Drug Administration (FDA) approved retifanlimab-dlwr (Zynyz), a PD-1–blocking monoclonal antibody, with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC)....
Breast Parenchymal Phenotypes and Risk of Breast Cancer
Six parenchymal phenotypes were established that may be associated with a higher risk of developing breast cancer. Studies of these phenotypes identified by radiomics on mammograms demonstrated that these patterns were associated with an increased risk of invasive breast cancer, according to...
FDA Approves Therapy for NSCLC With High c-Met Protein Overexpression
On May 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis), a c-Met–directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic, nonsquamous, non–small cell lung cancer (NSCLC) with high c-Met ...
FDA Approves First Oral Therapy for Pheochromocytoma and Paraganglioma
On May 14, the U.S. Food and Drug Administration approved the oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan (Welireg) for patients aged 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). This represents the first FDA ...
Patient Advocacy Groups: Health-Care Programs Are Lifelines—Not Line Items
Forty nonprofit, nonpartisan organizations issued a statement this week to the House Energy & Commerce and Ways & Means Committees in regard to budget cuts and policy changes affecting Medicaid and health-care marketplaces. “As organizations representing millions of patients with serious...
Elective Nodal Radiotherapy for Oligorecurrent Nodal Prostate Cancer Metastases
In a phase II trial (PEACE V–STORM) reported in The Lancet Oncology, Ost et al found that elective nodal radiotherapy (ENRT) to the pelvis was associated with longer metastasis-free survival vs metastasis-directed therapy (MDT) in patients with pelvic nodal oligorecurrences of prostate cancer....
NCCN Clinical Practice Guidelines in Oncology: 2025 Updates
The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today, guidelines are available for more than 60 tumor types, subtypes, and related topics. During the NCCN’s 30th Annual...
FDA OCE Announces Project Interface Outreach Initiative
The Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA) has launched Project Interface to advance engagement and outreach to patients with cancer, advocacy organizations, and oncology experts. Its mission is to protect, promote, and advance public health by...
AI Model Estimates Biological Age and Predicts Survival in Patients With Cancer
FaceAge, a deep learning system, was developed and validated to estimate biological age from photographs of faces. In a study published in The Lancet Digital Health, FaceAge showed the ability to predict short-term outcomes in patients with cancer. The study demonstrated that FaceAge could...
Revisiting Margin Width Guidelines for Ductal Carcinoma In Situ and the Role of Routine Reexcision
For postmenopausal women with hormone receptor–positive ductal carcinoma in situ (DCIS) treated with breast-conserving surgery, whole-breast irradiation, and adjuvant endocrine therapy, reexcision to achieve wider surgical margins (≥ 1 mm or ≥ 2 mm) may not be necessary, according to data presented ...
Cohort Study Shows Benefits of Bilateral Salpingo-Oophorectomy Without Increased Health Risks
Patients with a history of breast cancer who are carriers of BRCA1 and BRCA2 pathogenic variants benefit from undergoing bilateral salpingo-oophorectomy, the results of a retrospective cohort study published in The Lancet Oncology showed. Women who had their ovaries and fallopian tubes removed...
GLP-1 Receptor Agonists Could Show Anticancer Benefits Beyond Weight Loss
First-generation weight-loss drugs like liraglutide and exenatide could show anticancer benefits beyond weight loss, according to findings from a retrospective, observational study presented by Sagy et al at the European Congress on Obesity (ECO) 2025 and simultaneously published in...
Combination of Weight Gain, Age at Pregnancy Could Increase Breast Cancer Risk
Investigators have found that the risk of developing breast cancer could be nearly three times higher among women who experience notable weight gain after the age of 20 years and either give birth after age 30 or don’t have children compared with those who give birth before age 30 and whose weight...
Annual or Biennial Multicancer Early Detection Screening Improves Patient Outcomes
The addition of multi-cancer early detection screening using a single blood sample improved patient outcomes whether conducted on an annual or every 2-year basis, according to findings from a modelling study published in BMJ Open. With earlier detection of disease progression, many cancers could...
In Case You Missed It: Additional Abstracts of Interest From AACR
Thousands of forward-looking research studies defined the 2025 American Association for Cancer Research (AACR) Annual Meeting. Here, aside from our fuller coverage of key presentations in The ASCO Post, we offer a snapshot of a few additional abstracts that may be of interest to cancer researchers...
FDA Approves At-Home Self-Collection Device for Cervical Cancer Screening
Teal Health announced the U.S. Food and Drug Administration’s (FDA) approval of the Teal Wand™, an at-home vaginal sample self-collection device for cervical cancer screening in the United States. The Teal Wand is a prescription device that will soon be available at getteal.com for individuals aged ...
FDA Approves Doublet for KRAS-Mutated, Recurrent, Low-Grade Serous Ovarian Cancer
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the combination of the dual RAF/MEK inhibitor avutometinib and the FAK inhibitor defactinib (Avmapki Fakzynja Co-pack) for adults with KRAS-mutated, recurrent, low-grade serous ovarian cancer (LGSOC) who have...
Patterns in Oncology Drug Use After Accelerated Approval Is Withdrawn
The accelerated approval program of the U.S. Food and Drug Administration (FDA) allows certain medications to be marketed if they are indicated for serious disease and there has been preliminary evidence of the drug’s efficacy. Pharmaceutical companies must then conduct postapproval trials to...
Collaborative Strategy Involving AI, Human Task-Sharing Could Help Minimize Mammogram Costs
When screening for breast cancer, the most effective strategy to utilize artificial intelligence (AI) may involve collaboration with human radiologists, according to a recent study published by Ahsen et al in Nature Communications. The findings could help shape how hospitals and clinics integrate...
Breast Cancer Radiotherapy: 1- vs 3-Week Course
A 1-week course of postsurgery radiotherapy demonstrated comparable safety and efficacy to the traditional 3-week regimen in patients with early-stage breast cancer, according to new findings presented by Brunt et al at the European Society for Radiotherapy and Oncology (ESTRO) 2025 Annual Meeting...
How Could So Many Physicians Have Failed Me?
The first sign that something was terribly wrong was in 2015, when I began to feel so fatigued that it was difficult to get out of bed even after 8 to 10 hours of sleep. I’ve been full of energy my whole life and couldn’t understand why I was so tired all the time. Then I began to experience...
Ablative Radiation Therapy for Resectable Pancreatic Ductal Adenocarcinoma
Ablative radiation therapy is considered to be an alternative to surgery, providing an effective noninvasive option for local treatment of many types of cancer, but it is unknown whether ablative radiation therapy is effective for pancreatic ductal adenocarcinoma. Surgery provides improved...
Remembering Roswell Park Leader Thomas B. Tomasi, Jr, MD, PhD
Thomas B. Tomasi, Jr, MD, PhD, who led Roswell Park Comprehensive Cancer Center as President and Chief Executive Officer from 1986 to 1996, died on March 23 at age 97. His tenure marked a renaissance at Roswell Park that elevated it to a place among the nation’s top cancer centers. The pinnacle of ...
Keith T. Flaherty, MD, FAACR, Elected as AACR President-Elect for 2025–2026
The members of the American Association for Cancer Research (AACR) have elected Keith T. Flaherty, MD, FAACR, as the AACR President-Elect for 2025–2026. He will assume the Presidency in April 2026 at the AACR Annual Meeting in San Diego. Dr. Flaherty is Director of Clinical Cancer Research and the ...
Rakesh K. Jain, PhD, FAACR, Honored With 2025 AACR Award for Lifetime Achievement in Cancer Research
The 2025 AACR Award for Lifetime Achievement in Cancer Research was presented to Rakesh K. Jain, PhD, FAACR, during the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago. This award honors individuals who have made significant fundamental contributions to cancer...
Quick Takes on Research Findings on Novel Therapies for Gynecologic Cancers
The 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer advanced the field with updates of practice-changing trials and other research that challenges the conventional approaches to treating gynecologic cancers. We have briefly captured some of that research here for readers ...
HIV-Related Structural Barriers in Cancer Care
Patients with human immunodeficiency virus (HIV) are less likely to receive potentially life-saving cancer treatment if they reside in communities with lower income levels and educational attainment, according to a recent study published by Islam et al in Cancer. Study Methods and Results...
Influence of ACA on Breast Reconstruction Disparities
Despite steady increases in the rates of immediate postmastectomy breast reconstruction, racial disparities in receipt of the procedure have persisted in the years since the implementation of the Affordable Care Act (ACA), according to a recent study published by Schafer et al in Plastic and...
Two- vs 8-Week Course of Radiotherapy for Prostate Cancer: 10-Year Follow-up
The phase III HYPO-RT-PC trial has shown that a shorter course of radiotherapy (2 weeks) for localized prostate cancer is just as safe and effective as the traditional 8-week schedule—even 10 years after treatment. The findings, presented at the European Society for Radiotherapy and Oncology's...
Molecular Profiling May Optimize Treatment for Endometrial Cancer
A major international study, PORTEC-4a, provides evidence that molecular profiling may safely reduce the need for radiotherapy in some women with early-stage endometrial cancer while identifying those who would benefit from more intensive treatment. The results, presented at ESTRO 2025, may mark a...
Five Major Advances in Radiotherapy for Anal and Rectal Cancer Presented at ESTRO 2025
Five pivotal studies presented at ESTRO 2025 showcase how radiotherapy is reshaping the landscape for anal and rectal cancers. From reduced-dose treatments to cutting-edge combinations with immunotherapy and chemotherapy, these innovations offer safer, more effective, and organ-preserving...
Smoking Cessation May Be Critical to Mitigate Burden of Second Primary Cancers
Investigators may have discovered a link between smoking and the risk of second primary cancers across various first primary cancer types, according to new findings presented by Sung et al at the 2025 American Association for Cancer Research (AACR) Annual Meeting (Abstract 4942/20). Study Methods...
New Treatment Approach Could Enhance Care for Aggressive Relapsed/Refractory T- and NK-Cell Lymphomas
Investigators have uncovered how a specific sequence of cancer therapies could improve outcomes among patients with relapsed/refractory mature T- and natural killer (NK)-cell lymphomas, according to a recent study published by Sorial et al in the British Journal of Haematology. Background...
Cancer Briefs From Digestive Disease Week 2025
Cancer-related studies were among the nearly 6,000 abstracts presented at Digestive Disease Week® (DDW) 2025, including research on artificial intelligence (AI) in patient communication, polyp detection, and colonoscopy prep. Use of AI in Patient Communication AI outperformed physicians in...
Early-Stage Stomach Cancer Diagnoses on the Rise
Stomach cancers are increasingly being diagnosed at less advanced, more treatable stages—a shift that marks major progress in detecting one of the deadliest forms of cancer, according to a study presented at Digestive Disease Week® (DDW) 2025 (Abstract Sa1374). “These trends suggest that...
Anal Cancer Rates Rising Most Among Older White and Hispanic Women
Anal cancer has been steadily increasing in the United States, with the biggest jumps among older women, especially White and Hispanic women, a new study presented at Digestive Disease Week 2025 (Abstract 76) found. According to the investigators, this shift challenges assumptions about high-risk...
Financial Toxicity Tumor Board: Can It Reduce Treatment Costs?
The Atrium Health Levine Cancer Institute established a Financial Toxicity Tumor Board in 2019. The board is the first known institutional-level intervention of its kind and functions like a traditional disease-focused multidisciplinary tumor board—with a singular focus on financial distress. Now,...
AML: MRD Testing Led to Survival Benefits in Subset of Patients
Sequential molecular measurable residual disease (MRD) testing and monitoring led to a survival benefit among younger patients with acute myeloid leukemia (AML) and NPM1 and FLT3-ITD mutations, according to the results of a study published in The Lancet Haematology. Patients with both mutations...
Use of CAD/CAM May Improve Jaw Reconstruction Outcomes Among Patients With Head and Neck Cancer
The use of computer-aided design and manufacturing (CAD/CAM) techniques for planning jaw reconstructions for patients with head and neck cancer undergoing free fibula reconstruction of the lower jaw may potentially shorten the duration of the surgery and reduce removal rates due to complications,...
Malaria Subtype May Be Linked to Development of Burkitt Lymphoma
Researchers may have uncovered the role of Plasmodium falciparum malaria in the development of Burkitt lymphoma, according to a recent study published by Ariera et al in The Journal of Immunology. Background Uncomplicated malaria occurs when a patient’s symptoms are nonspecific, including fever,...
Cannabis Use Disorder Significantly Increases Mortality Risk in Colorectal Cancer
Patients with colorectal cancer and a history of cannabis use disorder had a more than 20 times higher risk of mortality within 5 years than those without cannabis use order, according to the results of a study published in Annals of Epidemiology. The 5-year mortality rate in patients with a...
2025 ACS Cancer Prevention, Early Detection Report: Cancer Screening Rates, Modifiable Risk Factors
Investigators have uncovered mixed progress in major cancer risk factors, preventive behaviors, and screenings in the post–COVID-19 pandemic period among adults in the United States, according to a new study published by Bandi et al in Cancer Epidemiology, Biomarkers & Prevention. Background An ...
AACR 2025: Novel CAR T-Cell Therapy Induces Response in Patients With Advanced Thyroid Cancers
A novel chimeric antigen receptor (CAR) T-cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety profile in patients with two types of advanced thyroid cancer. Results from a small, first-in-human phase I trial were presented at the ...
